Literature DB >> 21153114

Different ultrastructural localization of VIP and prolactin in anterior pituitary cells of rats chronically treated with estrogen.

K Köves1, I L Chen, T J Görcs, J G Scammell, A Arimura.   

Abstract

In the present study we investigated the effect of a long-term estrogen treatment on the intracellular distribution of VIP immunoreactivity in pituitary prolactin cells using double-labeling immunocytochemistry. With the use of pre-embedding ABC method it was found that VIP immunoreactivity was associated with the outer surface of membrane-bound organelles, and was not found in secretory granules. However, prolactin immunoreactivity demonstrated by postembedding immunogold technique was mainly associated within the secretory granules of the same cells. The discrepancy between our and Hsu et al.'s results (1989), who observed VIP immunoreactivity in secretory granules of human anterior pituitary cells, may be owing to the overstimulation of VIP cells by estrogen. It is possible that estrogen treatment depleted the VIP content of the secretory granules and enhanced the cytosolic VIP. The appearance of an alternative form of VIP in estrogen-treated rats with preferential distribution in the cytosol cannot be excluded.

Entities:  

Year:  1996        PMID: 21153114     DOI: 10.1007/BF02738709

Source DB:  PubMed          Journal:  Endocrine        ISSN: 1355-008X            Impact factor:   3.633


  25 in total

1.  Innervation of different peptide-containing neurons in the hippocampus by GABAergic septal afferents.

Authors:  A I Gulyás; T J Görcs; T F Freund
Journal:  Neuroscience       Date:  1990       Impact factor: 3.590

2.  Vasoactive intestinal peptide in the anterior pituitary is increased in hypothyroidism.

Authors:  K S Lam; R M Lechan; N Minamitani; T P Segerson; S Reichlin
Journal:  Endocrinology       Date:  1989-02       Impact factor: 4.736

3.  Antisera to vasoactive intestinal polypeptide inhibit basal prolactin release from dispersed anterior pituitary cells.

Authors:  T C Hagen; M A Arnaout; W J Scherzer; D R Martinson; T L Garthwaite
Journal:  Neuroendocrinology       Date:  1986       Impact factor: 4.914

4.  Polypeptide with broad biological activity: isolation from small intestine.

Authors:  S I Said; V Mutt
Journal:  Science       Date:  1970-09-18       Impact factor: 47.728

5.  Effect of steroids on vasoactive intestinal peptide in discrete brain regions and peripheral tissues.

Authors:  W H Rotsztejn; J Besson; B Briaud; L Gagnant; G Rosselin; C Kordon
Journal:  Neuroendocrinology       Date:  1980-10       Impact factor: 4.914

6.  Quantification of vasoactive intestinal peptide immunoreactivity in the anterior pituitary glands of intact male and female, ovariectomized, and estradiol benzoate-treated rats.

Authors:  A J Carrillo; C J Phelps
Journal:  Endocrinology       Date:  1992-08       Impact factor: 4.736

7.  Recovery of rat prolactin cells following cessation of estrogen treatment.

Authors:  M Shiino; E G Rennels
Journal:  Anat Rec       Date:  1976-05

8.  Vasoactive intestinal polypeptide is synthesized in anterior pituitary tissue.

Authors:  M A Arnaout; T L Garthwaite; D R Martinson; T C Hagen
Journal:  Endocrinology       Date:  1986-11       Impact factor: 4.736

9.  Fine-structural heterogeneity and morphologic changes in rat pituitary prolactin cells after estrogen and testosterone treatment.

Authors:  H Nogami
Journal:  Cell Tissue Res       Date:  1984       Impact factor: 5.249

10.  Interaction between estradiol and prolactin on vasoactive intestinal peptide concentrations in the hypothalamus and in the anterior pituitary of the female rat.

Authors:  M Maletti; W H Rostene; L Carr; H Scherrer; D Rotten; C Kordon; G Rosselin
Journal:  Neurosci Lett       Date:  1982-10-23       Impact factor: 3.046

View more
  1 in total

1.  Effect of concomitant progesterone administration or the effect of removal of estrogen capsule on changes caused by long-term estrogen treatment in pituitary VIP immunoreactivities.

Authors:  Andrea Heinzlmann; Katalin Köves; György M Nagy
Journal:  Endocrine       Date:  2010-03-30       Impact factor: 3.633

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.